Raptor Pharmaceutical Inc. Announces Closing Of Underwritten Public Offering And Exercise In Full of Underwriters' Option To Purchase Additional Shares
NOVATO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases, today announced the closing of its underwritten public offering of 10,925,000 shares of its common stock at a public offering price of $9.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,425,000 additional shares of common stock. The aggregate gross proceeds before underwriting discounts and commissions and expenses of the offering payable by the company are approximately $98.3 million.
Citigroup, Leerink Partners and Cowen and Company acted as lead joint book-running managers for the offering. JMP Securities acted as lead manager and Janney Montgomery Scott acted as a co-manager for the offering.
A registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) and became automatically effective on March 30, 2015. This offering was made solely by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus related to the offering were filed with the SEC and are available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus related to the offering may also be obtained from Citigroup Global Markets Inc., Attention: c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York, 11717, or by phone at (800) 831-9146, or by email at prospectus@citi.com; or from the offices of Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by phone at (800) 808-7525, or by email at syndicate@leerink.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.
About Raptor Pharmaceutical
Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), and Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU.
CONTACT: COMPANY CONTACT: Kimberly Lee, D.O. Vice President, Corporate Strategy and Communications Raptor Pharmaceutical Corp. (415) 408-6351 INVESTOR CONTACT: Robert H. Uhl Westwicke Partners, LLC Managing Director (858) 356-5932 robert.uhl@westwicke.com MEDIA CONTACT: Cammy Duong Canale Communications (619) 849-5382 cammy@canalecomm.com
Help employers find you! Check out all the jobs and post your resume.